Navigation Links
A New Test Developed to Identify Suspected Bowel Cancer Patients

Researchers have announced a new test to identify patients who develop bowel cancer as they have a particular gene that could be at fault is unveiled today//.

An Edinburgh University team conducted the test study, and they presented their report in the New England Journal of Medicine. They explained that the tests would help to make certain that these patients could then get the best treatment and will help identify relatives with the same mutation who might have a great increase in the risk of cancer.

The researchers said that around 20,000 people in the general population are thought to have this exacting class of genetic defect, which is associated with a very high risk of cancer. They explained that the biggest challenge was to identify these people, so as to start preventive measures before the disease kicks in or very early in its stage, so as to have a much higher rates of success in controlling it. It was explained that this study that has been reported was a significant step towards this goal.

The researchers explained that the team had developed the test in a long-term study that involved 870 patients, primarily focusing on the faults in three genes, MLH1, MSH2 and MSH6, which are considered responsible for proteins that help to prevent the DNA damage that are linked with tumour development.

The findings of the team showed that 38, about4% of the patients had faulty genes, almost twice as many as suggested by previous estimates. Prof Malcolm Dunlop, one of the researcher said, 'In the long term, we hope the results of this study will help identify all bowel cancer patients who carry one of these gene faults and then offer tests to their relatives who have not yet developed cancer, so that we can prevent the development of cancer.'

Prof Alex Markham, the chief executive of Cancer Research UK, said: 'These are very valuable findings that will help scientists better understand the process of bowel
'"/>




Page: 1 2

Related medicine news :

1. Scientists Developed Map For Brain Molecular Communities
2. Scientists Developed Cheap Way To Assess Sleep
3. Diabetic Friendly Egg Developed In India
4. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
5. Cervical Cancer Vaccine To Be Developed In India
6. Anti-Microbial Coating For Use Over Biomedical Devices Developed
7. Cure for Osteoarthritis To Be Developed
8. Mice With Human Thought Processes Could Be Developed In The Future
9. Viagra Pill For Women To Be Developed
10. Male Contraceptive Pill Being Developed By Berlin Pharmaceutical
11. New Fertility Predictor Test Developed
Post Your Comments:
(Date:12/2/2008)...tCall/ -- Quest Diagnostics Incorporated (NYSE: ...testing, information and services, announced that ...thcare Conference in New York City today, December...cheduled to begin at 4:00 p.m. Eastern Time. , ...affirm its 2008 guidance for revenue growth of gre...
(Date:12/2/2008)...er with aprotinin, a drug commonly used to control...y, compared with lysine analogues, according to a ...9 to be published in the January 20th issue of C...dvisory panel will meet to decide on aprotinin use...the meeting. , The study, a systematic review o...
(Date:12/2/2008)...rstCall/ - NUCRYST Pharmaceuticals Corp., a develo...t infection and inflammation, announced today that...rity shareholder, The Westaim Corporation ("Westai...areholders to consider a return of capital of US$0...s to a return of capital of approximately US$15 mi...
(Date:12/2/2008)...e Efficacy of Commercially Available Hypomethylati... Eisai Corporation of North Americ...rst clinical trial evaluating the activity of Daco...za(R) (azacitidine) in adult patients with interme...ic syndromes (MDS), a potentially life-threatening...
Breaking Medicine News(10 mins):Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3
... of Public Health have reported that over the coun...eneficial as they can lower the risk of Parkinson’... took daily one ibuprofen tablet, men and women, f...eople seemed to have a 38% less chance of having P...
... increased calcium intake by drinking milk or othe...of Parkinson’s disease. Parkinson’s disease is a d...s are muscle tremors, muscle rigidity, decreased m...low voluntary movements, and a mask-like facial ex...
... out how to elevate the functional limitations of ...e researchers of Feinberg School of Medicine, US ...and old with arthritis. Functions, which were chec...ng to daily living and specialized activities of d...
...ncy is associated with dental problems. But are th...trong enough to affect the babies’ birth weight or...ew York University College of Dentistry, US, say t...a affect the pregnancy by causing pre-term deliver...
Other Medicine News:
(Date:12/1/2008)...e Call Scheduled for Tuesday, December 9 at 11:00 ..., , SOUTH SAN FRANCISCO, Calif., Dec. 1 /...Inc. (Nasdaq: SNSS ), a biopharmaceutical compan... of new oncology therapeutics, today announced new...id leukemia (AML) will be presented during the 50t...
(Date:11/28/2008)..., Germany, November 28 German biot...ship in specialized HIV monitoring and,AIDS patie...ng countries. In,the year 2008, 2.5 million patie...obust and highly affordable "CyFlow" system, suppo...ith HIV/AIDS. Due to introduction of the,Partec i...
(Date:11/26/2008)...ed to 406 Subjects , , FRANKLIN, Mass., Nov...TC Bulletin Board: PLCSF) announced today that it ...Drug Administration (FDA) for its U.S. pivotal tri...alGuard System(TM) and associated therapy in the ..., , The FDA also approved PLC,s request to ...
(Date:11/25/2008)...ANCISCO, Calif., Nov. 25 ... a biopharmaceutical company focused on,innovativ... be exploring,strategic alternatives for its prec...ompany to focus its resources on the clinical deve..., and to support the initial commercialization of,...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 1STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 2STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 3SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 1SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 2SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 3The ABCs of childhood zs 3A Snoring may be chronic despite surgery 14382 1The ABCs of childhood zs 3A Snoring may be chronic despite surgery 14382 2Low exposure to asbestos like mineral from Montana vermiculite may up lung disease risk 2504 1Low exposure to asbestos like mineral from Montana vermiculite may up lung disease risk 2504 2
...ll/ - Research,collaborators with Oncolytics Biote...poster presentation covering REOLYSIN(R),clinical ...ology,(ASCO) Annual Meeting, to be held June 1-5, ...ncolytics, U.K. Phase I systemic,administration tr...ase I Study of,Wild-Type Oncolytic Reovirus Admini...
...007 - A therapeutic,vaccine developed by the Germa...ew hope for cancer patients. The results of a,succ...d to an,international audience at the Annual Confe...y (ASCO) in Chicago, USA. ASCO is the,most importa...,world-wide., The active substance VPM4001, an imm...
Other Medicine Technology:Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001 2
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...
Medicine Products: